Results 21 to 30 of about 490 (134)

Virtual Bioequivalence Assessment and Dissolution Safe Space Exploration for Fixed-Dose Metformin–Glyburide Tablet Using Physiologically Based Biopharmaceutics Modeling [PDF]

open access: yesPharmaceutics
Background/Objectives: Fixed-dose combinations (FDCs) hold significant clinical value for the management of hypertension, diabetes and other chronic diseases.
Chenshuang Zhao   +3 more
doaj   +3 more sources

Sex‐Related Differences in Physiologically‐Based Biopharmaceutics Modeling [PDF]

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Physiologically based pharmacokinetic (PBPK) and physiologically‐based biopharmaceutics (PBBM) modeling are valuable tools in drug development, allowing mechanistic predictions of drug absorption and disposition.
Marianela Chavarría‐Rojas   +4 more
doaj   +3 more sources

A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the in Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP [PDF]

open access: yesPharmaceutics, 2020
The application of in silico modeling to predict the in vivo outcome of an oral drug product is gaining a lot of interest. Fully relying on these models as a surrogate tool requires continuous optimization and validation.
Marival Bermejo   +2 more
exaly   +7 more sources

Surge Dose® Formulations of NSAIDs Provide for Ultra-Rapid and Consistent Drug Absorption in Both the Fasted and Fed State as Predicted by Physiologically Based Biopharmaceutics Modelling [PDF]

open access: yesPharmaceutics
Background/Objectives: This paper describes the use of physiologically based biopharmaceutics modelling (PBBM) to predict the effect of food on diclofenac and ibuprofen absorption from ultra-rapid-release Surge Dose® tablets.
Harri Dickinson   +4 more
doaj   +3 more sources

Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling [PDF]

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Omaveloxolone is a nuclear factor (erythroid‐derived 2)‐like 2 activator approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years, with a recommended dosage of 150 mg orally once daily on an
Xavier J. H. Pepin   +5 more
doaj   +3 more sources

In Silico Evaluation of the Biopharmaceutical and Pharmacokinetic Behavior of Metronidazole from Coated Colonic Release Matrix Tablets [PDF]

open access: yesPharmaceutics
Background: Physiologically based biopharmaceutics modeling (PBBM) models can help to predict drug release and in vivo absorption behaviors. Colon drug delivery systems have gained interest over the past few years due to the advantages they provide in ...
Roberto Arévalo-Pérez   +2 more
doaj   +5 more sources

Adult and pediatric physiologically‐based biopharmaceutics modeling to explain lamotrigine immediate release absorption process [PDF]

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Physiologically‐based biopharmaceutics modeling (PBBM) has potential to accelerate the development of new drug and formulations. An important application of PBBM is for special populations such as pediatrics that have pharmacokinetics dependent on the ...
Edilainy Rizzieri Caleffi‐Marchesini   +10 more
doaj   +3 more sources

A text mining study on the utility of physiologically based pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) in formulation development [PDF]

open access: yesMacedonian Pharmaceutical Bulletin, 2023
14th Central European Symposium on Pharmaceutical Technology, 28th - 30th September, Ohrid, N.
Krstevska, Aleksandra   +3 more
openaire   +3 more sources

Emerging Perspectives on Leveraging Physiologically Based Biopharmaceutics Modeling (PBBM) for BCS Class III Biowaivers: A Webinar Summary [PDF]

open access: yesJournal of Pharmaceutical Sciences
The regulatory framework for Biopharmaceutics Classification System (BCS) class III drug products provides a pathway for streamlined biowaivers in drug development, eliminating the need for expensive and time-consuming bioavailability and bioequivalence studies while maintaining quality standards.
Lanyan Fang   +2 more
exaly   +4 more sources

Physiologically Based Biopharmaceutics Modelling—Best Scientific Practices to Define Drug Product Performance, Latest Regulatory and Industry Perspectives: Workshop Summary Report [PDF]

open access: yesPharmaceutics
In November 2024, a two-day meeting entitled “PBBM—Best Scientific Practices to Define Drug Product Performance: Latest Regulatory and Industry Perspectives” was organised by the Academy of Pharmaceutical Sciences Biopharmaceutics Focus group and hosted ...
Mark McAllister   +23 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy